Keck School Faculty

David I Quinn, MD
David I Quinn, MD
Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine
NOR 3453 Health Sciences Campus Los Angeles
David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

Dr. Quinn's current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.

Castle Connolly Medical: America's Top Doctors, 2010

USC Norris Cancer Center and Hospital: The Spirit of Norris Award, 2002

Royal Australasian College of Physicians: Vincent Fairfax Family Fellowship, 2001

National Health and Medical Research Council of Australia: Neil Hamilton Fairley Fellowship, 2000-2003

St. Vincent's Clinic Foundation: The David Wilson Travelling Fellowship, 2000

Postgraduate Medical Council of New South Wales: Distinguished Contribution Award, 2000

National Health and Medical Research Council of Australia: Postgraduate Medical Scholarship, 1996-1999

University of New South Wales: Honours First Class Bachelor of Medicine, Bachelor of Surgery, 1987

University of New South Wales: Gordon Lowe Memorial Prize, 1987

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providersUrol Oncol. 2017 07; 35(7):459. e15-459. e24. . View in PubMed

Cancer transcriptomic profiling from rapidly enriched circulating tumor cells Int J Cancer. 2020 Feb 09. . View in PubMed

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma J Clin Oncol. 2020 Feb 07; JCO1902044. . View in PubMed

Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature Clin Genitourin Cancer. 2020 Jan 07. . View in PubMed

Editorial Comment J Urol. 2020 02; 203(2):336-337. . View in PubMed

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 10, RECIST 1. 1, and PSA response criteria. Theranostics. 2020; 10(7):3254-3262. . View in PubMed

Accurate blood pressure during patient arm movement: the Welch Allyn Connex Spot Monitor's SureBP algorithm Blood Press Monit. 2019 Feb; 24(1):42-44. . View in PubMed

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma Invest New Drugs. 2019 08; 37(4):755-762. . View in PubMed

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2019 02; 566(7745):E11-E12. . View in PubMed

Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer Urol Oncol. 2019 01; 37(1):1-11. . View in PubMed

Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis Eur Urol. 2018 11; 74(5):611-620. . View in PubMed

Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 08; 16(4):e719-e727.. View in PubMed

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations Cancer Discov. 2018 07; 8(7):812-821. . View in PubMed

A Universal Standard for the Validation of Blood Pressure Measuring Devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement Hypertension. 2018 03; 71(3):368-374. . View in PubMed

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial Ann Oncol. 2018 12 01; 29(12):2371-2378. . View in PubMed

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer J Clin Oncol. 2018 06 01; 36(16):1579-1587. . View in PubMed

HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018 02 08; 554(7691):189-194. . View in PubMed

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival Clin Cancer Res. 2018 10 01; 24(19):4662-4671. . View in PubMed

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 Cancer Treat Res Commun. 2018; 16:18-23. . View in PubMed

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) Clin Cancer Res. 2017 Dec 01; 23(23):7199-7208. . View in PubMed

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer Cancer. 2017 Dec 01; 123(23):4566-4573. . View in PubMed

Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients Clin Genitourin Cancer. 2017 Sep 06. . View in PubMed

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions Ann Oncol. 2017 Jul 01; 28(7):1484-1494. . View in PubMed

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer Clin Genitourin Cancer. 2017 12; 15(6):742-749. . View in PubMed

Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease J Nucl Med. 2017 12; 58(12):2026-2037. . View in PubMed

Comparative effectiveness of screening strategies for colorectal cancer Cancer. 2017 05 01; 123(9):1516-1527. . View in PubMed

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet. 2017 01 07; 389(10064):67-76. . View in PubMed

AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth Prostate. 2016 May; 76(6):597-608. . View in PubMed

Fabrication of conductive gelatin methacrylate-polyaniline hydrogels Acta Biomater. 2016 Mar; 33:122-30. . View in PubMed

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile CancerClin Genitourin Cancer. 2016 10; 14(5):450-456. e1. . View in PubMed

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Onco Targets Ther. 2016; 9:5825-5837. . View in PubMed

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial J Clin Oncol. 2016 05 01; 34(13):1500-9. . View in PubMed

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project† Ann Oncol. 2015 Dec; 26(12):2392-8. . View in PubMed

Assessing the damage control resuscitation: development, drivers and direction Emerg Med Australas. 2015 Oct; 27(5):485-7. . View in PubMed

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma Br J Cancer. 2015 Aug 11; 113(4):616-25. . View in PubMed

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms Urol Oncol. 2015 May; 33(5):245-60. . View in PubMed

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial Int J Cancer. 2015 Apr 15; 136(8):1856-62. . View in PubMed

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial Target Oncol. 2015 Mar; 10(1):45-53. . View in PubMed

Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases Radiology. 2015 Feb; 274(2):624-5. . View in PubMed

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review BMC Cancer. 2014 Dec 16; 14:966. . View in PubMed

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. . View in PubMed

Chromoplexy and hypoxic microenvironment drives prostate cancer Lancet Oncol. 2014 Dec; 15(13):1419-1421. . View in PubMed

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma Cancer. 2014 Sep 01; 120(17):2684-93. . View in PubMed

Carboplatin's fourth decade: still searching for its sweet spot Ann Oncol. 2014 Aug; 25(8):1457-8. . View in PubMed

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States Urol Oncol. 2014 Jul; 32(5):637-44. . View in PubMed

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer J Clin Oncol. 2014 Apr 10; 32(11):1136-42. . View in PubMed

Effect of mechanical behavior of the brachial artery on blood pressure measurement during cuff inflation and cuff deflation Blood Press Monit. 2014 Apr; 19(2):120. . View in PubMed

Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. . View in PubMed

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases Urology. 2014 Jan; 83(1):159-65. . View in PubMed

Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patientsUrol Oncol. 2014 Jan; 32(1):52. e1-9. . View in PubMed

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. . View in PubMed

Differentiating mTOR inhibitors in renal cell carcinoma Cancer Treat Rev. 2013 Nov; 39(7):709-19. . View in PubMed

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol. 2013 Aug; 14(9):893-900. . View in PubMed

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors Invest New Drugs. 2013 Aug; 31(4):1016-22. . View in PubMed

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer J Nucl Med. 2013 Aug; 54(8):1195-201. . View in PubMed

Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology J Clin Oncol. 2013 Jan 01; 31(1):131-61. . View in PubMed

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings Eur Urol. 2013 Jan; 63(1):58-66. . View in PubMed

Immune response to sipuleucel-T in prostate cancer Cancers (Basel). 2012 Apr 18; 4(2):420-41. . View in PubMed

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer Ann Oncol. 2012 Apr; 23(4):968-73. . View in PubMed

Blood cells and their use in active immunotherapy of prostate cancer Hum Vaccin Immunother. 2012 Apr; 8(4):528-33. . View in PubMed

Factors influencing post-recurrence survival in bladder cancer following radical cystectomy BJU Int. 2012 Mar; 109(6):846-54. . View in PubMed

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer J Clin Oncol. 2012 Feb 10; 30(5):507-12. . View in PubMed

FDG PET/CT demonstration of pancreatic metastasis from prostate cancer Clin Nucl Med. 2011 Oct; 36(10):961-2. . View in PubMed

A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma Int J Clin Oncol. 2011 Oct; 16(5):494-9. . View in PubMed

Experience with sorafenib and adverse event management Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32. . View in PubMed

Cabazitaxel in prostate cancer: stretching a string Lancet. 2010 Oct 02; 376(9747):1119-20. . View in PubMed

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. . View in PubMed

Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35. . View in PubMed

Fasting and cancer treatment in humans: A case series report Aging (Albany NY). 2009 Dec 31; 1(12):988-1007. . View in PubMed

An evaluation of the completeness of reporting of childhood tuberculosis Eur Respir J. 2009 Jul; 34(1):176-9. . View in PubMed

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study Anticancer Drugs. 2009 Mar; 20(3):179-84. . View in PubMed

Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience World J Urol. 2009 Feb; 27(1):39-44. . View in PubMed


Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma Clin Pharmacokinet. 2009; 48(3):199-209. . View in PubMed

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer BJU Int. 2008 Dec; 102(11):1601-6. . View in PubMed

A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94. . View in PubMed

Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells Int J Oncol. 2006 Jul; 29(1):225-35. . View in PubMed

Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol. 2006 Apr; 175(4):1245-52. . View in PubMed

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. . View in PubMed

EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival Oncogene. 2006 Feb 02; 25(5):769-80. . View in PubMed

Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial J Thorac Oncol. 2006 Feb; 1(2):126-34. . View in PubMed

Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer. 2005 Dec; 4(3):181-6.. View in PubMed

Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines Mol Cancer Ther. 2005 Jul; 4(7):1105-13. . View in PubMed

EphB4 expression and biological significance in prostate cancer Cancer Res. 2005 Jun 01; 65(11):4623-32. . View in PubMed

Angiogenesis-targeted therapies in prostate cancer Clin Prostate Cancer. 2004 Dec; 3(3):165-73. . View in PubMed

Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients Cancer. 2004 Jun 15; 100(12):2627-36. . View in PubMed

A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer J Urol. 2003 Nov; 170(5):1798-803. . View in PubMed

Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer Oncogene. 2003 Sep 04; 22(38):6005-12. . View in PubMed

Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression Prostate Cancer Prostatic Dis. 2003; 6(2):174-81. . View in PubMed

Frequent loss of estrogen receptor-beta expression in prostate cancer Cancer Res. 2001 Jul 15; 61(14):5331-5. . View in PubMed

Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer Cancer Res. 2001 Jan 15; 61(2):423-7. . View in PubMed

Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue Clin Cancer Res. 1999 Oct; 5(10):2810-9. . View in PubMed

Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer Cancer Res. 1999 May 15; 59(10):2324-8. . View in PubMed

Analysis of diagnostic metabolites by capillary electrophoresis-mass spectrometry J Chromatogr B Biomed Sci Appl. 1999 Apr 30; 727(1-2):43-52. . View in PubMed

Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience Cancer. 1999 Apr 15; 85(8):1758-64. . View in PubMed

Acute renal impairment after immersion and near-drowning J Am Soc Nephrol. 1999 Feb; 10(2):382-6. . View in PubMed

An audit of oestrogen implant hormone replacement therapy Aust N Z J Obstet Gynaecol. 1998 Nov; 38(4):455-60. . View in PubMed

Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40 Cancer Res. 1998 May 01; 58(9):1773-8. . View in PubMed

Drug interactions of clinical importanceAn updated guide. Drug Saf. 1995 Jun; 12(6):393-452. . View in PubMed

Adverse drug reactions and their measurement in the rheumatic diseases J Rheumatol. 1995 May; 22(5):983-8. . View in PubMed

Powered by SC CTSI
Go to Top